Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,178 across all filing types
Latest filing 2023-11-07 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for a generic drug application. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content focuses on the regulatory approval news and product details, not on financial results, management changes, or detailed financial data. The document length is about 5,326 characters, which is relatively short and typical for a press release. There is no indication of financial statements, earnings data, or detailed report content. This fits best under the category of a Capital/Financing Update (CAP) or Regulatory Filings (RNS). However, since it is a disclosure pursuant to a listing regulation about a regulatory approval event, it is more aligned with Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2023-11-07 English
Lupin Receives Tentative Approval from U.S. FDA for Canagliflozin and Metformin Hydrochloride Extended-Release Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative approval from the U.S. FDA for a generic drug application. It is addressed to stock exchanges and references regulatory disclosure requirements (Regulation 30 of SEBI Listing Regulations). The content is a corporate announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. It does not contain financial statements, management analysis, or detailed investor presentation material. It is not a report publication announcement since it is the announcement itself, not about the timing or availability of a report. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement and disclosure pursuant to listing obligations without fitting into more specific categories like earnings release or capital update.
2023-11-07 English
Loss of Share Certificates
Regulatory Filings Classification · 100% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the stop transfer request related to those shares. The document is addressed to stock exchanges and signed by the company secretary. It is a regulatory compliance filing related to share certificate handling and does not contain financial statements, management discussion, or report data. The document length is short (2930 characters) and it is a formal regulatory communication. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance certificate and not a financial report or announcement of a report.
2023-11-06 English
Intimation regarding loss of share certificate by shareholder.
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. It details the loss of share certificates and the request for stop transfer, addressed to stock exchanges. The document is short (2929 characters) and is a regulatory compliance communication rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or any report publication. It is not related to board changes, voting results, or capital changes. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance certificate and does not fit other specific categories.
2023-11-06 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a licensing and supply agreement between Lupin Limited and Zydus Lifesciences Limited to co-market a drug in India. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which pertains to material events or information. The content focuses on the business agreement and product details, not on financial results, management changes, or regulatory filings. The document is not a financial report, earnings release, or management discussion. It is a corporate announcement about a licensing agreement, which fits best under Capital/Financing Update (CAP) as it relates to a business deal impacting company operations and potential revenue streams. The document length is sufficient and contains substantive information about the agreement, not just a brief notification or report publication announcement.
2023-11-03 English
Lupin and Zydus Sign Licensing Agreement for Co-marketing Saroglitazar Mg, a critical treatment for chronic liver diseases in India.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a licensing and supply agreement between Lupin Limited and Zydus Lifesciences Limited to co-market a drug called Saroglitazar Mg in India. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations, specifically Regulation 30, which pertains to disclosure of material events. The content focuses on the business agreement and product details, not on financial results, management changes, or regulatory filings. The document is about a corporate announcement of a commercial agreement rather than a financial report or regulatory filing. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a licensing and supply agreement impacting the company's commercial operations and potentially its capital structure or revenue streams. The document length is sufficient and contains substantive information about the agreement, not just a brief notice or report publication announcement.
2023-11-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.